Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of canocapavir plus nucleos(t)ide analogs versus nucleos(t)ide analog monotherapy in adults with chronic hepatitis B with incomplete viral suppression
CTR20252445Phase 3Active
- Sponsor
- Zhimeng Biopharma
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Canocapavir in Chronic Hepatitis B (CHB), sponsored by Zhimeng Biopharma. Started Aug 2025; status: active.
02
Drugs
Canocapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20252445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252445.